Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Polyrizon Ltd. ( (PLRZ) ) is now available.
On October 6, 2025, Polyrizon Ltd. announced positive pre-clinical results for its PL-14 Allergy Blocker formulation, which demonstrated significant efficacy in blocking allergens. The study showed that PL-14 effectively limited allergen penetration, suggesting robust protection even under extreme conditions. This development positions Polyrizon favorably in the growing Allergy Immunotherapy market, projected to expand significantly over the next decade. The company plans to advance its preclinical program and initiate clinical studies to further develop PL-14 and other candidates within its C&C platform.
More about Polyrizon Ltd.
Polyrizon Ltd. is a biotechnology company focused on developing innovative intranasal products utilizing its proprietary Capture & Contain (C&C) platform. The company specializes in medical device hydrogels delivered as nasal sprays, forming a protective barrier against viruses and allergens. Polyrizon is also advancing its technology for the intranasal delivery of active pharmaceutical ingredients.
Average Trading Volume: 6,134,107
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.53M
For detailed information about PLRZ stock, go to TipRanks’ Stock Analysis page.